Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized StudyDaniel R. Gomez, John V. Heymach, José A. Karam et al.|Journal of Clinical Oncology|2019Cited by 1.3k
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 studyDaniel R. Gomez, John V. Heymach, George R. Blumenschein et al.|The Lancet Oncology|2016Cited by 1.1k
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilitiesCarl M. Gay, Lauren A. Byers, C. Allison Stewart et al.|Cancer Cell|2021Cited by 930
Adenovirus-Mediated p53 Gene Transfer in Advanced Non-Small-Cell Lung CancerStephen G. Swisher, Martin Waugh, Jack A. Roth et al.|JNCI Journal of the National Cancer Institute|1999Cited by 497
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-upHumam Kadara, Roy S. Herbst, Murim Choi et al.|Annals of Oncology|2016Cited by 209